学术周报 · IF≥10 或专科旗舰刊

消化内科领域文献阅读汇编

2026年第46周 (2026-11-13) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
收录论文
15
临床研究
6
基础研究
9
IF≥20
3
IF 10-20
10
子领域
9
期刊种类
13
数据日期
2026-11-13

★本周 Top 10 高影响力文献

#论文期刊IF
1PKA signaling controls ILC3 homeostasis and IL-23-mediated inflammation in the gut.Nature immunologyIF 26.5
2Endosomal signalling of protease-activated receptor-2 amplifies histamine-induced pain of irritable ...GutIF 24.6
3What's Coming Up Next? The Physiology of Gastroparesis and GLP-1 Agonists.Annual review of physiologyIF 20.3
4The FOXA2-BNIP3 axis alleviates acute necrotizing pancreatitis by promoting mitophagy in pancreatic ...AutophagyIF 18.6
5Immunometabolic and epigenetic reprogramming in inflammatory bowel disease: from mechanistic circuit...Biomarker researchIF 14.6
6Sex and Etiology Differences in Overall Survival and Adverse Liver Events in Hepatocellular Carcinom...MedCommIF 14.1
7A Pan-Hepatic T-Cell Atlas Identifies Disease-Specific Immune Dysfunction and Therapeutic Targets fo...MedCommIF 14.1
8Adaptive dual-programming magnetic soft robot with lifelike behavior.Science advancesIF 13.9
9Caspase-5 couples the cleavage of endosomal Cav1.2-C terminus to cytosolic LPS release and barrier d...Pharmacological researchIF 12.2
10Comprehensive Immunoprofiling and Multi-Omics Modeling Reveal Key Immune Features Associated with Di...Cancer lettersIF 11.8

Ŧ期刊分布统计

期刊篇数IF
The American journal of gastroenterology2IF 8.5
MedComm2IF 14.1
Critical reviews in food science and nutrition1IF 10.6
Pharmacological research1IF 12.2
Autophagy1IF 18.6
Nature immunology1IF 26.5
Journal for immunotherapy of cancer1IF 11.7
Cancer letters1IF 11.8
ESMO open1IF 10.6
Gut1IF 24.6

1炎症性肠病/IBD (4篇)

临床研究 (1篇)

The American journal of gastroenterology IF 8.5 2026-11-12 PMID: 43016241
Safety is important when selecting advanced therapies for inflammatory bowel disease (IBD). Safety data for anti-interleukin therapy (anti-IL) or vedolizumab come from trials with limited follow-up, and direct comparisons with anti-tumor necrosis factors (anti-TNFs) for incident cancer are lacking. We evaluated cancer incidence in patients with IBD treated with anti-IL therapy or vedolizumab versus anti-TNFs. We conducted a retrospective cohort study of adults with IBD and no prior cancer who initiated anti-IL therapy, vedolizumab or anti-TNFs. Our primary outcome was incident cancer from 90 days after therapy initiation through discontinuation. We calculated incidence rates and performed Cox proportional hazards models. We identified 4,019 advanced therapy starts: 995 anti-IL, 692 vedolizumab, and 2,332 anti-TNF starts, with mean therapy duration of 1096 days. In multivariable analysis, there was a trend towards a lower hazard of all cancers among anti-IL users compared to anti-TNF users (HR 0.47; 95% CI 0.21-1.04), which was significant on sensitivity analyses. There was no difference in hazard of skin cancers (HR 1.56; 95% CI 0.39-6.15); however, the hazard of non-skin cancer was significantly lower among anti-IL users compared to anti-TNF users (HR 0.28; 95% CI 0.09-0.81). When comparing vedolizumab to anti-TNFs, there was no significant difference in the hazard of all cancer (HR 0.52, 95% CI 0.24-1.12) and non-skin cancer (HR 0.63, 95% CI 0.29-1.39). We found no evidence of an increased cancer risk with anti-IL therapy compared with anti-TNF therapy in patients with IBD. There was no difference in the cancer risk between vedolizumab and anti-TNF therapy.
中文摘要:在炎症性肠病(IBD)中选择高级疗法时安全性至关重要。抗白介素疗法(anti-IL)或维得利珠单抗的安全性数据多来自随访有限的试验,且缺乏与抗肿瘤坏死因子(anti-TNF)相比的癌症发病率直接比较。我们评估了接受anti-IL疗法或维得利珠单抗治疗的IBD患者与接受anti-TNF治疗患者的癌症发病率。本研究是一项回顾性队列研究,纳入无既往癌症病史且启动anti-IL疗法、维得利珠单抗或anti-TNF治疗的成年IBD患者。主要结局为从治疗开始90天后至停药期间的癌症新发病例。我们计算了发病率并进行了Cox比例风险模型分析。共识别出4,019次高级疗法起始:其中995次为anti-IL,692次为维得利珠单抗,2,332次为anti-TNF,平均治疗持续时间为1,096天。在多变量分析中,与anti-TNF使用者相比,anti-IL使用者的全癌风险呈降低趋势(HR 0.47;95% CI 0.21-1.04),在敏感性分析中具有统计学意义。皮肤癌的风险无差异(HR 1.56;95% CI 0.39-6.15);然而,anti-IL使用者的非皮肤癌风险显著低于anti-TNF使用者(HR 0.28;95% CI 0.09-0.81)。在比较维得利珠单抗与anti-TNF时,全癌风险(HR 0.52,95% CI 0.24-1.12)和非皮肤癌风险(HR 0.63,95% CI 0.29-1.39)均无显著差异。我们发现IBD患者使用anti-IL疗法相比anti-TNF疗法并无增加癌症风险的证据。维得利珠单抗与anti-TNF疗法之间的癌症风险也无差异。

基础研究 (3篇)

Pharmacological research IF 12.2 2026-11-12 PMID: 43020400
Gram-negative bacterial outer membrane vesicles (OMVs) deliver lipopolysaccharide (LPS) into intestinal epithelial cells to drive ulcerative colitis (UC) progression, yet the precise mechanisms orchestrating cytosolic LPS release and subsequent pathogenic signaling remain elusive. Here, we identify a non-canonical, caspase-5-dependent signaling axis that couples endosomal Cav1.2 cleavage to barrier disruption. We show that the voltage-gated calcium channel Cav1.2 is aberrantly upregulated in the intestinal epithelium of UC patients and murine colitis models. Upon OMV internalization, increased caspase-5 is recruited to early endosomes, where it promotes the generation of the Cav1.2 C-terminal fragment (CCt), thereby facilitating LPS release from OMVs into the cytosol. Mechanistically, caspase-5 is required for and co-translocates with CCt into the nucleus, where they co-bind to the proximal CDH1 promoter region, repressing E-cadherin transcription and impairing barrier integrity. Furthermore, by rationally designing, we identify a small molecule DC-SG003 that enhances the interaction between the upstream orchestrator SNX10 and the E3 ubiquitin ligase MYCBP2. This promotes the ubiquitination-mediated degradation of SNX10, thereby providing a compelling pharmacological strategy to dismantle this cascade and restore epithelial barrier function.
中文摘要:革兰氏阴性菌外膜囊泡(OMVs)将脂多糖(LPS)递送至肠道上皮细胞以驱动溃疡性结肠炎(UC)进展,但调控胞质LPS释放及后续致病信号的确切机制尚不明确。本研究鉴定了一条非经典的Caspase-5依赖性信号轴,该轴将内体Cav1.2切割与屏障破坏偶联。我们发现电压门控钙通道Cav1.2在UC患者及小鼠结肠炎模型的肠道上皮中异常上调。OMV内化后,增加的Caspase-5被招募至早期内体,促进Cav1.2C端片段(CCt)的生成,从而促进LPS从OMVs释放至胞质。机制上,Caspase-5是必需的并与CCt共转运入核,二者共同结合于CDH1启动子近端区域,抑制E-cadherin转录并损害屏障完整性。此外,通过合理设计,我们鉴定出小分子DC-SG003可增强上游调控因子SNX10与E3泛素连接酶MYCBP2之间的相互作用。这促进了SNX10的泛素化介导降解,为拆解该级联反应并恢复上皮屏障功能提供了有力的药理学策略。
Nature immunology IF 26.5 2026-11-11 PMID: 43015493
Group 3 innate lymphoid cells (ILC3s) are tissue-protective lymphocytes that are enriched in the healthy gut and depleted in gastrointestinal disorders. Here we created a single-cell atlas to define how ILC3s respond to distinct stimuli, observing that prostaglandin engages protein kinase A (PKA) to upregulate tissue-protective factors. In contrast, the canonical activator interleukin-23 (IL-23) decreased negative regulators of PKA, including PRKAR1A. Lineage-specific Prkar1a deletion reduced ILC3s and increased susceptibility to enteric infection in mice. PRKAR1A was not required in early life but continuously preserved ILC3 homeostasis in adults by restraining PKA activity. Overproduction of IL-23 was sufficient to reduce PRKAR1A in ILC3s and increase PKA signaling that provoked gut inflammation. Finally, ILC3s from the healthy human intestine expressed PRKAR1A, which was downregulated by IL-23 or in inflammatory bowel disease. These results demonstrate that regulated PKA signaling is essential for tissue-protective ILC3s, while IL-23 drives aberrant PKA signaling to elicit intestinal inflammation.
中文摘要:第三组固有淋巴细胞(ILC3)是富集于健康肠道并在胃肠道疾病中耗竭的组织保护性淋巴细胞。本研究构建了单细胞图谱以定义 ILC3 对不同刺激的反应,观察到前列腺素通过激活蛋白激酶 A(PKA)上调组织保护因子。相比之下,经典激活剂白细胞介素-23(IL-23)降低了 PKA 的负调控因子,包括 PRKAR1A。谱系特异性 Prkar1a 缺失在小鼠中减少了 ILC3 数量并增加了肠道感染的易感性。PRKAR1A 在生命早期并非必需,但在成年期通过抑制 PKA 活性持续维持 ILC3 稳态。IL-23 的过度产生足以降低 ILC3 中的 PRKAR1A 水平并增加 PKA 信号传导,从而引发肠道炎症。最后,健康人类肠道中的 ILC3 表达 PRKAR1A,该表达在炎症性肠病中或受 IL-23 作用时被下调。这些结果表明,受调控的 PKA 信号对组织保护性 ILC3 至关重要,而 IL-23 驱动异常的 PKA 信号以引发肠道炎症。
Biomarker research IF 14.6 2026-11-06 PMID: 42995613
Inflammatory bowel disease (IBD) is a chronic, immune-mediated disorder of the gastrointestinal tract and an escalating global public health challenge, particularly in newly industrializing regions. Its etiology and pathogenesis remain incompletely understood, although disrupted homeostasis between the intestinal microbiota and the mucosal immune system is implicated. Macrophages and T cells contribute to the balance between tissue injury and repair. Increasing evidence suggests that metabolic state and epigenetic programs interact to influence immune cell function. Under hypoxic and inflammatory stress, glucose, lipid, and amino acid metabolism can undergo remodeling, including shifts between glycolysis and oxidative phosphorylation, altered fatty-acid utilization, changes in tryptophan and methionine metabolism, and fluctuations in methyl-donor availability. Metabolic cues may influence chromatin regulation and immune signaling through acetylation, methylation, lactylation, palmitoylation, phosphorylation, and other modifications. These processes can affect effector programs, the T helper 17-regulatory T cell balance, macrophage inflammatory gene expression, inflammasome activation, and interleukin-10-related signaling, with potential implications for mucosal barrier repair and inflammatory amplification. However, the causal roles of these metabolic and epigenetic alterations in IBD remain to be clarified: they may contribute to disease initiation, arise as accompanying features of the disease state, or amplify inflammation once it is established. This review synthesizes current advances in metabolic reprogramming and epigenetic regulation in macrophages and T cells, examining immunometabolic nodes that link environmental stress to chromatin remodeling. We further summarize emerging therapeutic strategies targeting metabolic and epigenetic pathways, assess evidence from preclinical and clinical studies, and discuss interventions directed at immunometabolic checkpoints.
中文摘要:炎症性肠病(IBD)是一种慢性免疫介导的胃肠道疾病,也是全球日益严峻的公共卫生挑战,尤其在新兴工业化地区。其病因和发病机制尚不完全清楚,但肠道微生物群与黏膜免疫系统之间的稳态失衡被认为参与其中。巨噬细胞和T细胞有助于维持组织损伤与修复之间的平衡。越来越多的证据表明,代谢状态和表观遗传程序相互作用以影响免疫细胞功能。在缺氧和炎症应激下,葡萄糖、脂质和氨基酸代谢可能发生重塑,包括糖酵解与氧化磷酸化之间的转换、脂肪酸利用的改变、色氨酸和甲硫氨酸代谢的变化以及甲基供体可用性的波动。代谢线索可能通过乙酰化、甲基化、乳酸化、棕榈酰化、磷酸化和其他修饰影响染色质调节和免疫信号传导。这些过程可以影响效应程序、T辅助17细胞与调节性T细胞的平衡、巨噬细胞炎症基因表达、炎性小体激活和白细胞介素-10相关信号传导,对黏膜屏障修复和炎症放大具有潜在意义。然而,这些代谢和表观遗传改变在IBD中的因果作用仍有待阐明:它们可能促进疾病的发生,作为疾病状态的伴随特征出现,或在炎症建立后加剧炎症。本综述综合了巨噬细胞和T细胞中代谢重编程和表观遗传调节的最新进展,考察了将环境应激与染色质重塑联系起来的免疫代谢节点。我们进一步总结了靶向代谢和表观遗传途径的新兴治疗策略,评估了临床前和临床研究中的证据,并讨论了针对免疫代谢检查点的干预措施。

2消化道早癌筛查 (4篇)

临床研究 (4篇)

The American journal of gastroenterology IF 8.5 2026-11-12 PMID: 43016246
Existing colonoscopy quality metrics have limited utility for trainees. In particular, the adenoma detection rate may reflect trainer rather than trainee competence. Polyp miss rates may be more objective and feasible metrics of trainee colonoscopy quality. The aim of this study was to assess the proximal colon adenoma miss rate (AMR) and sessile serrated polyp miss rate (SMR) among gastroenterology trainees using a tandem colonoscopy study design. We prospectively recruited adult patients scheduled for screening or surveillance colonoscopy during endoscopy blocks with one of six high-quality trainers. Trainees performed the insertion with attending supervision. The trainee then performed independent withdrawal and inspection of the proximal colon (cecum to splenic flexure), identifying polyps without attending input. Subsequently, the attending performed a second complete inspection of the proximal colon; polyps that were identified on the second pass were considered missed polyps. In total, 134 patients underwent colonoscopy by 13 gastroenterology trainees over a 17-month period. The overall proximal colon neoplastic (adenoma and serrated) polyp miss rate was 42.6%. Among these, they missed 38.1% of tubular adenomas and 58.9% of sessile serrated polyps in the proximal colon. Approximately 67% of the missed neoplastic polyps were ≤5mm. Trainee AMR and SMR decreased with increasing colonoscopy experience. Trainees miss over 40% of proximal colon neoplastic polyps, including the majority of right sided sessile serrated polyps. Measuring polyp miss rates using tandem colonoscopy is a novel and feasible approach to objectively assessing colonoscopy quality among gastroenterology trainees.
中文摘要:现有的结肠镜质量指标对培训医师的效用有限。特别是腺瘤检出率可能反映的是带教医师而非培训医师的能力。息肉漏诊率可能是评估培训医师结肠镜质量的更客观且可行的指标。本研究旨在通过串联结肠镜研究设计,评估消化内科培训医师的近端结肠腺瘤漏诊率和无蒂锯齿状息肉漏诊率。我们在内镜时段内前瞻性招募了接受筛查或监测结肠镜检查的成年患者,由六位高质量带教医师之一负责。培训医师在带教监督下完成进镜,随后独立进行近端结肠(从盲肠至脾曲)的退镜和检查,并在不带教干预的情况下识别息肉。随后,带教医师对近端结肠进行第二次完整检查;在第二次检查中发现的息肉被视为漏诊息肉。在17个月期间,共有134名患者由13名消化内科培训医师进行了结肠镜检查。总体近端结肠肿瘤性(腺瘤和锯齿状)息肉漏诊率为42.6%。其中,他们漏诊了近端结肠38.1%的管状腺瘤和58.9%的无蒂锯齿状息肉。约67%的漏诊肿瘤性息肉直径小于等于5毫米。随着结肠镜经验的增加,培训医师的腺瘤漏诊率和无蒂锯齿状息肉漏诊率下降。培训医师漏诊了超过40%的近端结肠肿瘤性息肉,包括大多数右侧无蒂锯齿状息肉。使用串联结肠镜测量息肉漏诊率是一种新颖且可行的方法,可客观评估消化内科培训医师的结肠镜质量。
Journal for immunotherapy of cancer IF 11.7 2026-11-11 PMID: 43014827
Immune-related hepatitis (IRH) and pneumonitis (IRP) occur more frequently in East Asian versus European patients receiving immune checkpoint inhibitors (ICIs). Human leukocyte antigen (HLA) allelic variations, which differ substantially between ancestries, have been associated with immune-related adverse events (irAEs) risk and ICI efficacy in European cohorts, but large-scale validation in Asian populations is lacking. Clarifying these ancestry-specific biomarkers is critical for advancing precision immunotherapy. We conducted a single-center retrospective study of 3261 East Asian patients with lung cancer treated with ICIs (2018–2023). Of these, 380 patients developed IRH and 248 developed IRP. Each case group was randomly matched 1:3 with controls without that irAE (IRH: 1,140; IRP: 744), resulting in 1793 patients for HLA genotyping. Time-varying Cox models and landmark analyses assessed irAE-overall survival (OS) associations, adjusting for immortal time bias and clinical covariates. Sample weighted Cox-proportional hazard models were conducted to estimate the associations of HLA alleles with the occurrence of irAE and survival. With a median follow-up of 24.9 months (range 0.2–90 months), we identified two independent predictive factors: (1) Mild IRH (grade 1–2) was significantly associated with prolonged OS (p=0.004), with a median onset time of 2.17 months. This association remained consistent across landmark analyses at 3, 6, 9, 12 months and median onset time, supporting its predictive value. (2) HLA-DQB1*06:01 was independently associated with poorer OS (p=0.0004, false discovery rate: 0.03), an effect observed regardless of IRH occurrence. Notably, HLA-DQB1*06:01 frequency in our cohort (8.5%) was substantially higher than reported in European ancestry (0.7%), consistent with known ethnic differences in HLA architecture. In contrast, we found no significant associations between HLA variants and the risk of developing IRH or IRP, suggesting that HLA’s predictive impact operates through mechanisms distinct from irAE susceptibility. This study provides the first large-scale evidence that mild IRH is an early favorable predictive indicator and HLA-DQB1*06:01 identifies a high-risk subgroup, collectively enabling actionable risk stratification in ICI-treated East Asian patients. The observed ethnic differences in HLA allele frequencies and their distinct associations with survival outcomes underscore the critical need for ancestry-informed precision oncology approaches in cancer immunotherapy.
中文摘要:免疫检查点抑制剂治疗期间,东亚患者发生免疫相关性肝炎和肺炎的频率高于欧洲患者。人类白细胞抗原等位基因变异在祖先间存在显著差异,已证实与欧洲队列中免疫相关不良事件风险及免疫检查点抑制剂疗效相关,但缺乏针对亚洲人群的大规模验证。明确这些具有祖先特异性的生物标志物对于推进精准免疫治疗至关重要。本研究开展了一项单中心回顾性研究,纳入2018年至2023年间接受免疫检查点抑制剂治疗的3261名东亚肺癌患者。其中380例发生免疫相关性肝炎,248例发生免疫相关性肺炎。每个病例组均按1:3比例与未发生相应不良事件的对照组进行随机匹配(免疫相关性肝炎组1140例,免疫相关性肺炎组744例),共1793名患者进行人类白细胞抗原基因分型。采用时间依赖性Cox模型和地标分析评估不良事件与总生存期的关联,并校正 immortal time bias 及临床协变量。通过样本加权Cox比例风险模型估算人类白细胞抗原等位基因与不良事件发生及生存的关系。中位随访时间为24.9个月(范围0.2至90个月),我们确定了两个独立的预测因素:轻度免疫相关性肝炎(1至2级)与总生存期延长显著相关(p=0.004),中位发病时间为2.17个月。该关联在3、6、9、12个月及中位发病时间的地标分析中保持一致,支持其预测价值。人类白细胞抗原DQB1*06:01与较差的总生存期独立相关(p=0.0004,错误发现率0.03),无论是否发生免疫相关性肝炎均观察到该效应。本队列中该等位基因频率为8.5%,显著高于欧洲祖先报道的0.7%,符合已知的人类白细胞抗原架构种族差异。相比之下,未发现人类白细胞抗原变异与发生免疫相关性肝炎或肺炎风险之间的显著关联,表明人类白细胞抗原的预测作用通过区别于不良事件易感性的机制发挥作用。本研究提供了首个大规模证据,表明轻度免疫相关性肝炎是早期有利预测指标,而人类白细胞抗原DQB1*06:01可识别高危亚群,共同实现接受免疫检查点抑制剂治疗的东亚患者的可行风险分层。观察到的人类白细胞抗原等位基因频率种族差异及其与生存结果的不同关联,强调了在癌症免疫治疗中采用基于祖先信息的精准肿瘤学方法的重要性。
ESMO open IF 10.6 2026-11-11 PMID: 43014085
CA209-8M4 is a prospective phase II trial evaluating the addition of nivolumab to total neoadjuvant treatment (TNT) in patients with locally advanced rectal cancer (LARC). Patients with LARC (T3-4Nany or TanyN1) up to 12 cm from the anal verge received standard chemoradiation (CRT) followed by chemoimmunotherapy (CIMT): six cycles of standard mFOLFOX6 and nivolumab at 240 mg. We defined a novel primary endpoint, combining pathological complete response (pCR) rate among operated patients and long-term (≥12 months) clinical complete response (cCR) rate for those electing watchful waiting, into a composite endpoint of modified pCR (mpCR) rate. Between April 2019 and March 2024, 29 patients were enrolled, median age 53 years, 72.4% male; 96.6% of tumors were cT3 or cT4, 69.0% cN+, and 96.6% microsatellite stable. Median distance from the anal verge was 7 cm; 51.7% of patients had grade ≥3 adverse events (AEs) during CIMT, including one fatality (mesenteric inflammation), attributed most likely to CRT's unresolved toxicity. Immune-mediated AEs occurred in four patients (13.8%): grade 3 diabetes mellitus (1) and grade 1 hepatitis (3), including one with asymptomatic hyper/hypothyroidism. Twenty-eight patients (96.6%) are assessable for mpCR: 6 of the 15 operated achieved pCR, and 13 were not operated with cCR ≥12 months, leading to a 67.9% mpCR rate. With a median follow-up of 43.5 months (range 25.0-84.1+), all 28 assessable pts are alive with no evidence of disease. The estimated 3-year disease-free survival and 5-year overall survival rates of the entire group are 93% [95% confidence interval (CI) 84-100] and 97% (95% CI 90-100), respectively. The addition of nivolumab to standard TNT in LARC seems safe and may enhance its effectiveness, with encouraging mpCR and survival rates. A multicenter randomized trial, further evaluating this strategy, is ongoing.
中文摘要:CA209-8M4是一项前瞻性II期试验,评估在局部晚期直肠癌(LARC)患者中于全程新辅助治疗(TNT)基础上联合纳武利尤单抗的效果。入组距离肛缘12 cm以内的LARC患者(T3-4Nany或TanyN1),接受标准放化疗(CRT)后行化疗免疫治疗(CIMT):6个周期标准mFOLFOX6联合240 mg纳武利尤单抗。本研究定义了一个新的主要终点,将手术患者的病理完全缓解(pCR)率与选择等待观察患者长期(≥12个月)临床完全缓解(cCR)率合并为改良pCR(mpCR)率复合终点。2019年4月至2024年3月共入组29例患者,中位年龄53岁,男性占72.4%;96.6%肿瘤为cT3或cT4期,69.0%为cN+,96.6%为微卫星稳定。距离肛缘中位距离为7 cm;CIMT期间51.7%患者发生≥3级不良事件(AE),包括1例死亡(肠系膜炎症),最可能归因于CRT未解决的毒性。免疫介导的AE见于4例患者(13.8%):3级糖尿病1例,1级肝炎3例,其中1例伴有无症状的高/甲状腺功能减退。28例患者(96.6%)可评估mpCR:15例手术患者中有6例达到pCR,13例未手术患者cCR≥12个月,mpCR率达67.9%。中位随访43.5个月(范围25.0-84.1+),所有28例可评估患者均存活且无疾病证据。全组估计3年无病生存率和5年总生存率分别为93% [95%置信区间(CI)84-100]和97%(95% CI 90-100)。在LARC的标准TNT基础上联合纳武利尤单抗似乎安全且可能提高其有效性,mpCR和生存率令人鼓舞。一项进一步评估该策略的多中心随机试验正在进行中。
MedComm IF 14.1 2026-11 PMID: 43011222
Sex-associated differences in hepatocellular carcinoma (HCC) prognosis remain incompletely characterized across major etiologies. In this retrospective international multicenter cohort study, we included 7623 consecutive patients with newly diagnosed HCC from 41 centers in five countries and evaluated the associations of sex and four-level etiology with overall survival (OS) and the first adverse liver event (hepatic decompensation, liver failure, or liver-related death). Sex-related OS was evaluated in the full cohort, after 1:1 propensity-score matching (1351 men and 1351 women), and in a multivariable Cox model including recorded initial treatment modality; cause-specific Cox and Fine-Gray models evaluated adverse liver events. Five-year OS was 24.3% in women and 22.0% in men. Female sex was associated with lower mortality before matching (hazard ratio [HR], 0.90; 95% CI, 0.85-0.97), after matching (HR, 0.91; 95% CI, 0.84-0.99; p = 0.024), and after multivariable adjustment (HR, 0.91; 95% CI, 0.85-0.98; p = 0.010). Male sex was associated with a higher hazard of adverse liver events (cause-specific HR, 1.26; 95% CI, 1.11-1.43; subdistribution HR [sHR], 1.23; 95% CI, 1.08-1.40). Alcohol-related and metabolic dysfunction-associated steatotic liver disease (MASLD)-related HCC had higher liver-event hazards than hepatitis B virus (HBV)-related HCC. For OS, the global sex-by-etiology interaction was not significant (p = 0.866). Female sex was associated with modestly better outcomes, although the China-dominant cohort limits generalizability.
中文摘要:肝癌预后中的性别差异在不同病因中尚未完全明确。本研究为一项回顾性国际多中心队列研究,纳入来自五个国家41个中心的7623例新诊断肝癌患者,评估性别与四级病因对总生存期及首次不良肝脏事件(肝衰竭、肝功能衰竭或肝相关死亡)的关联。在全队列、经倾向评分匹配后(男女各1351例)及包含初始治疗方式的多元Cox模型中评估性别相关的总生存期;采用特定原因Cox模型和Fine-Gray模型评估不良肝脏事件。女性五年总生存率为24.3%,男性为22.0%。匹配前女性死亡风险较低(HR 0.90,95%CI 0.85-0.97),匹配后(HR 0.91,95%CI 0.84-0.99;p=0.024)及多元调整后的结果一致(HR 0.91,95%CI 0.85-0.98;p=0.010)。男性不良肝脏事件风险更高(特定原因HR 1.26,95%CI 1.11-1.43;亚分布HR 1.23,95%CI 1.08-1.40)。酒精相关及代谢功能障碍相关脂肪性肝病相关肝癌的肝脏事件风险高于乙型肝炎病毒相关肝癌。总生存期的性别与病因交互作用无统计学意义(p=0.866)。女性总体预后略优,但受限于以中国人群为主的队列,其普遍适用性受限。

3肝炎 (1篇)

临床研究 (1篇)

Critical reviews in food science and nutrition IF 10.6 2026-11-12 PMID: 43018453
Aflatoxin B1 (AFB1) is a mycotoxin, or fungal toxin, that contaminates maize, peanuts, and tree nuts grown in warm regions of the world. It causes liver cancer and is synergistic with chronic hepatitis B virus (HBV) infection to multiplicatively increase cancer risk. Peanuts (also called groundnuts) are a major source of aflatoxin exposure in many populations worldwide. We conducted a systematic data review to examine the occurrence of AFB1 in peanut food products in 106 nations. We then conducted a dietary exposure assessment based on this occurrence dataset and consumption of peanuts in these nations, to compare trends across the time periods from 1990 to 2024. 22 nations experienced a substantial increase in aflatoxin exposure through peanut consumption, and 22 nations experienced a substantial decrease. Changes in exposure are largely driven by changes in intake levels. Many sub-Saharan African populations have alarmingly high levels of aflatoxin exposure, due to high contamination coupled with high consumption. Detection methods are shown to demonstrate recent improvements in sensitivity. These findings are important given the health risks of high aflatoxin exposure; most notably liver cancer.
中文摘要:黄曲霉毒素B1(AFB1)是一种真菌毒素,污染全球温暖地区种植的玉米、花生和坚果。它可引发肝癌,并与慢性乙型肝炎病毒(HBV)感染协同作用,呈乘法效应增加癌症风险。花生是全球许多人群黄曲霉毒素暴露的主要来源。本研究进行了系统数据回顾,以考察106个国家花生食品中AFB1的检出情况。随后基于该检出数据集及各国花生消费量,开展了膳食暴露评估,比较了1990年至2024年间的趋势变化。结果显示,22个国家通过花生消费导致的黄曲霉毒素暴露显著增加,另有22个国家显著减少。暴露水平的变化主要受摄入量变化的驱动。由于高污染水平与高消费量的叠加,许多撒哈拉以南非洲人群的黄曲霉毒素暴露水平令人担忧地偏高。检测方法的灵敏度近期有所提升。鉴于高剂量黄曲霉毒素暴露的健康风险,尤其是肝癌风险,上述发现具有重要意义。

4胰腺炎 (1篇)

基础研究 (1篇)

Autophagy IF 18.6 2026-11-12 PMID: 42980125
Acute necrotizing pancreatitis (ANP) is a severe inflammatory pancreatic disease characterized by pancreatic necrosis and systemic inflammation, with complex pathogenesis, rapid progression, and poor prognosis. Mitochondrial dysfunction in pancreatic acinar cells represents a pivotal early event in ANP; however, mitophagy, a central component of mitochondrial quality control, remains poorly characterized in terms of its role, regulatory networks, and therapeutic potential in ANP. In this study, we demonstrated that BNIP3 (BCL2 interacting protein 3) expression was significantly downregulated in patients with ANP and negatively correlated with inflammatory severity. Consistently, BNIP3-mediated mitophagy was impaired in the pancreatic tissue of ANP mouse models. Notably, restoration of BNIP3 expression using a novel adeno-associated virus targeting pancreatic tissue (AAV-PAN)-Bnip3 gene therapy vector alleviated pancreatic necrosis and systemic inflammatory injury, promoted mitophagy, and inhibited mitochondrial dysfunction and oxidative stress. Mechanistically, BNIP3-dependent mitophagy facilitated the clearance of damaged mitochondria and prevented mitochondrial DNA (mtDNA) release into the cytosol, thereby suppressing AIM2 (absent in melanoma 2) inflammasome activation and subsequent acinar cell pyroptosis. Furthermore, we identified the transcription factor FOXA2 (forkhead box A2) as a direct upstream regulator that bound to the Bnip3 promoter and positively regulated its expression. FOXA2 was downregulated in ANP, whereas pancreas-specific FOXA2 overexpression activated BNIP3-mediated mitophagy and conferred protection against inflammatory injury. Together, these findings uncovered a previously unrecognized mechanism whereby the FOXA2-BNIP3-AIM2 axis mitigated pancreatic and systemic inflammatory injury in ANP by enhancing mitophagy to restrain mtDNA-dependent AIM2 inflammasome activation, highlighting the FOXA2-BNIP3-AIM2 axis as a promising target for gene therapy.Abbreviations: AAV: adeno-associated virus; AAV-PAN: adeno-associated virus targeting pancreatic tissue; AAV8: adeno-associated virus serotype 8; ACTB/β-actin: actin, beta; AIM2: absent in melanoma 2; AMY: amylase; ANOVA: analysis of variance; ANP: acute necrotizing pancreatitis; ANXA5/annexin V: annexin A5; AP: acute pancreatitis; ATP: adenosine triphosphate; BNIP3: BCL2 interacting protein 3; CASP1: caspase 1; CCK: cholecystokinin; CGAS: cyclic GMP-AMP synthase; ChIP: chromatin immunoprecipitation; CON: control; CTSI: computed tomography severity index; DAMP: danger/damage-associated molecular pattern; DAPI: 4',6-diamidino-2-phenylindole; DEGs: differentially expressed genes; DHE: dihydroethidium; DNA: deoxyribonucleic acid; dsDNA: double-stranded DNA; EGFP: enhanced green fluorescent protein; ELISA: enzyme-linked immunosorbent assay; EtBr: ethidium bromide; FITC: fluorescein isothiocyanate; FOXA2: forkhead box A2; FUNDC1: FUN14 domain containing 1; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GOT1/AST: glutamic-oxaloacetic transaminase 1, soluble; GPT/ALT: glutamic pyruvic transaminase, soluble; GSDMD: gasdermin D; H&E: hematoxylin and eosin; HC: healthy control; IgG: immunoglobulin G; IL1B/IL-1β: interleukin 1 beta; IL6/IL-6: interleukin 6; KEGG: Kyoto encyclopedia of genes and genomes; LDH: lactate dehydrogenase; LV: lentivirus; MAP: mild acute pancreatitis; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MAP1LC3B/LC3B: microtubule associated protein 1 light chain 3 beta; MDA: malondialdehyde; MPO: myeloperoxidase; mRNA: messenger RNA; MSAP: moderately severe acute pancreatitis; mtDNA: mitochondrial DNA; MUT: mutant; nc: negative control; N-GSDMD: N-terminal fragment of GSDMD; OCT: optimal cutting temperature; PBS: phosphate-buffered saline; PCR: polymerase chain reaction; PFA: paraformaldehyde; PI: propidium iodide; PINK1: PTEN induced kinase 1; PPI: protein-protein interaction; PRKN/parkin: parkin RBR E3 ubiquitin protein ligase; qPCR: quantitative polymerase chain reaction; RNA: ribonucleic acid; ROS: reactive oxygen species; SAP: severe acute pancreatitis; SD: standard deviation; siRNA: small interfering RNA; SOD: superoxide dismutase; SQSTM1/p62: sequestosome 1; STING1: stimulator of interferon response cGAMP interactor 1; TBK1: TANK binding kinase 1; TEM: transmission electron microscopy; Tert: telomerase reverse transcriptase; TNF/TNF-α: tumor necrosis factor; TOMM20/TOM20: translocase of outer mitochondrial membrane 20; vg: vector genomes; WT: wild type; ΔΨm: mitochondrial membrane potential.
中文摘要:急性坏死性胰腺炎是一种以胰腺坏死和全身炎症为特征的严重炎症性胰腺疾病,其发病机制复杂、进展迅速且预后不良。胰腺腺泡细胞中的线粒体功能障碍是急性坏死性胰腺炎的关键早期事件;然而,作为线粒体质量控制核心组成部分的线粒体自噬,其在急性坏死性胰腺炎中的作用、调控网络及治疗潜力尚不明确。本研究表明,BNIP3在急性坏死性胰腺炎患者中表达显著下调,且与炎症严重程度呈负相关。一致地,在急性坏死性胰腺炎小鼠模型胰腺组织中,BNIP3介导的线粒体自噬功能受损。值得注意的是,使用靶向胰腺组织的新腺相关病毒AAV-PAN-Bnip3基因治疗载体恢复BNIP3表达,可减轻胰腺坏死和全身炎症损伤,促进线粒体自噬,并抑制线粒体功能障碍及氧化应激。机制上,BNIP3依赖的线粒体自噬促进了受损线粒体的清除,防止线粒体DNA释放至胞质,从而抑制AIM2炎性小体激活及随后的腺泡细胞焦亡。此外,我们鉴定出转录因子FOXA2作为直接上游调控因子,其与Bnip3启动子结合并正向调节其表达。在急性坏死性胰腺炎中FOXA2表达下调,而胰腺特异性过表达FOXA2可激活BNIP3介导的线粒体自噬并对炎症损伤提供保护作用。综上所述,这些发现揭示了一种先前未被认识的机制,即FOXA2-BNIP3-AIM2轴通过增强线粒体自噬以限制mtDNA依赖的AIM2炎性小体激活,从而减轻急性坏死性胰腺炎中的胰腺及全身炎症损伤,突显了该轴作为基因治疗靶点的潜力。

5肝癌 (1篇)

基础研究 (1篇)

Cancer letters IF 11.8 2026-11-11 PMID: 43014538
Comprehensive profiling of peripheral immune cells has shown prognostic and disease-monitoring value across multiple cancers, but its clinical relevance in hepatocellular carcinoma (HCC), particularly unresectable HCC, remains insufficiently defined. To address this gap, we performed integrated peripheral immunoprofiling combining T-cell receptor (TCR) repertoire sequencing, flow cytometry-based T-cell phenotyping, bulk RNA sequencing, and public single-cell RNA-seq analysis in healthy donors, resectable HCC patients, and unresectable HCC patients. This design enabled characterization of HCC-associated and stage-associated peripheral immune alterations and identification of immunotherapy-relevant features in unresectable HCC. Single-cell analysis and flow cytometry revealed remodeling of circulating T-cell states in unresectable HCC, including reduced naïve-like compartments, enrichment of Treg-like cells, and increased memory/effector differentiation. TCR repertoire analysis showed reduced diversity, increased clonal dominance, altered V-J gene usage, decreased interindividual sharing, and convergent motif-level alterations, with early CD4+ TCR perturbations in resectable HCC and more pronounced CD8+ repertoire restriction in unresectable disease. Exploratory GLIPH-based motif analysis, HLA inference, and peptide-HLA binding prediction suggested candidate motif-HLA antigen associations involving hepatitis virus-derived antigens and recurrent HCC mutation-derived candidate neoantigens, although experimental validation is required. Bulk RNA-seq of peripheral CD8+ T cells revealed higher Activation/Effector function, Exhaustion, and Anergy signature scores in both resectable and unresectable HCC than in HDs, with no significant differences between the two HCC groups, whereas the Chemokine/Chemokine receptor signature was specifically increased in unresectable HCC. The overall IFN-response signature did not differ significantly among the three groups. Integrative machine-learning models were then developed using 818 peripheral immune-related features. Among them, the random forest (RF) model effectively distinguished healthy donors, resectable HCC patients, and unresectable HCC patients, with consistently high sensitivity and area under the curve (AUC) in both cross-validation and an independent validation cohort. In unresectable HCC patients receiving immunotherapy, four features derived from TCR-seq and T-cell subset profiling discriminated responders (CR/PR) from non-responders (SD/PD) in univariate analyses, while multivariate prioritization further highlighted ULBP1 as a consistently prioritized response-associated feature that requires validation in an independent cohort. Overall, this study supports comprehensive peripheral immune profiling as an exploratory framework for identifying stage-associated immune alterations and candidate biomarkers to inform personalized immunotherapy strategies in HCC.
中文摘要:外周免疫细胞的全面谱系分析在多种癌症中显示出预后和疾病监测价值,但在肝细胞癌特别是不可切除肝细胞癌中的临床相关性仍定义不足。为填补这一空白,我们对健康供体、可切除肝细胞癌患者及不可切除肝细胞癌患者进行了整合的外周免疫谱系分析,结合T细胞受体TCR库测序、基于流式细胞术的T细胞表型分析、批量RNA测序以及公共单细胞RNA-seq数据。该设计旨在表征与肝细胞癌相关及分期相关的周围免疫改变,并识别不可切除肝细胞癌中与免疫治疗相关的特征。单细胞分析与流式细胞术揭示了不可切除肝细胞癌中循环T细胞状态的重组,包括初始样区室减少、调节性T细胞样细胞富集以及记忆/效应分化增加。TCR库分析显示多样性降低、克隆优势增加、V-J基因使用改变、个体间共享减少及收敛性基序水平改变,其中可切除肝细胞癌早期出现CD4+ TCR扰动,而不可切除疾病中CD8+库限制更为明显。探索性GLIPH基序分析、HLA推断及肽-HLA结合预测提示涉及肝炎病毒衍生抗原及复发性肝细胞癌突变衍生候选新抗原的候选基序-HLA抗原关联,但需实验验证。不可切除与可切除肝细胞癌患者外周CD8+ T细胞的批量RNA-seq显示激活/效应功能、耗竭及无能特征评分均高于健康供体,两组间无显著差异,而趋化因子/趋化因子受体特征仅在不可切除肝细胞癌中特异性增加。三组间整体干扰素反应特征无显著差异。随后利用818个外周免疫相关特征开发了集成机器学习模型。其中随机森林模型能有效区分健康供体、可切除及不可切除肝细胞癌患者,在交叉验证及独立验证队列中均表现出持续的高敏感性与曲线下面积。在接受免疫治疗的不可切除肝细胞癌患者中,单变量分析显示来自TCR测序和T细胞亚群谱系的四个特征能区分响应者(完全/部分缓解)与非响应者(疾病稳定/进展),多变量优先排序进一步突出ULBP1为一致的响应相关特征,需在独立队列中验证。总体而言,本研究支持全面外周免疫谱系分析作为识别分期相关免疫改变及候选生物标志物的探索性框架,以指导肝细胞癌个性化免疫治疗策略。

6肠易激/IBS/功能性胃肠病 (1篇)

基础研究 (1篇)

Gut IF 24.6 2026-11-11 PMID: 42156171
Proteases and histamine, co-secreted by mast cells and bacteria, sensitize colonic nociceptors and contribute to irritable bowel syndrome (IBS) pain. To determine whether irreversible proteolytic cleavage of protease-activated receptor-2 (PAR2) and its continued activity in endosomes amplify and sustain otherwise transient pronociceptive actions of histamine receptors (HRs) to cause recurrent pain, the defining symptom of IBS. We investigated PAR2 and H1R coexpression in nociceptors using RNAscope and assessed the consequences of coactivation using electrophysiological assays of nociceptor sensitization and biophysical measurements of receptor and effector activity. PAR2 and H1R were coexpressed by human and mouse dorsal root ganglion nociceptors. Intracolonic infusion of fecal supernatants from IBS patients with elevated histamine and proteolytic activity enhanced mechanosensitivity of colonic nociceptors in mice. Antagonists of PAR2 or H1R abolished this response. Combined administration of subthreshold concentrations of trypsin and histamine replicated the effects of fecal supernatant and caused hyperexcitability of isolated nociceptors. Pre-activation with trypsin sensitized histamine-induced hyperexcitability in nociceptors from wild-type but not Par2−/− mice. Endocytosis inhibitors prevented this hypersensitivity, consistent with sustained endosomal signaling of PAR2 and persistent nociceptor hyperexcitability. Trypsin amplified histamine-induced activation of H1R and β-arrestin2 and Gαq effectors at the plasmalemma and in endosomes. Conversely, histamine did not sensitize trypsin-induced hyperexcitability of neurons, in line with the inability of histamine to induce sustained nociceptor hypersensitivity. By amplifying and maintaining the otherwise transient actions of H1R and possibly other pain receptors, persistent PAR2 endosomal signaling makes a dominant contribution to IBS-related colonic pain.
中文摘要:蛋白酶和组胺由肥大细胞和细菌共同分泌,可致敏结肠伤害性感受器并导致肠易激综合征(IBS)疼痛。为确定蛋白酶激活受体2(PAR2)不可逆的蛋白水解裂解及其在内体中的持续活性是否放大并维持组胺受体(HRs)原本短暂的促痛作用从而导致IBS的定义性症状复发性疼痛,本研究利用RNAscope技术检测了伤害性感受器中PAR2与H1R的共表达情况,并通过伤害性感受器致敏的电生理测定及受体和效应器活性的生物物理测量评估了共同激活的后果。人和小鼠背根神经节伤害性感受器均共表达PAR2和H1R。向小鼠结肠内灌注来自组胺和蛋白水解活性升高的IBS患者的粪上清液增强了结肠伤害性感受器的机械敏感性,而PAR2或H1R拮抗剂可消除该反应。联合施用亚阈值的胰蛋白酶和组胺复制了粪上清液的效果并引起分离的伤害性感受器过度兴奋。野生型但非Par2−/−小鼠的伤害性感受器经胰蛋白酶预激活后对组胺诱导的过度兴奋产生致敏作用。内吞抑制剂阻止了这种超敏反应,这与PAR2持续的內体信号传导及伤害性感受器的持续过度兴奋一致。胰蛋白酶在质膜和内体中放大了组胺诱导的H1R、β-arrestin2和Gαq效应剂的激活。相反,组胺未能致敏胰蛋白酶诱导的神经元过度兴奋,这与组胺无法诱导持续的伤害性感受器超敏反应相符。通过放大并维持H1R及其他可能疼痛受体的原本短暂作用,持续的PAR2內体信号传导对IBS相关的结肠疼痛做出了主要贡献。

7肝炎/肝癌 (1篇)

基础研究 (1篇)

MedComm IF 14.1 2026-11 PMID: 43001071
Single-cell transcriptomics has greatly advanced insight into hepatic immunity and immunotherapy. However, the absence of an integrated atlas spanning multiple hepatic diseases limits systematic comparisons of immune heterogeneity and dynamics. Here, we established a Pan-HEpatic single-cell Atlas of T cells (Pheat), covering 139 donors, 255 blood and liver samples spanning chronic hepatitis (chronic hepatitis B/C [CHB/CHC], alcohol-associated hepatitis, metabolic dysfunction-associated steatohepatitis), cirrhosis, hepatocellular carcinoma (HCC), and healthy controls (HC), and delineated profound population-, tissue-, and disease-level heterogeneity of 624,215 T cells, with emphasis on CD8+ exhausted T cells (Tex) and CD4+ regulatory T cells (Treg). Within Tex, intrahepatic precursor Tex (Texpre) were depleted in CHB compared with healthy controls and other hepatic diseases. Disease-specific checkpoint dominance (4-1BB in CHB, TIGIT in HCC) in Texpre was identified and experimentally validated. Panobinostat was predicted and validated to reinvigorate Texpre in CHB patients. In parallel, effector Treg (eTreg) accumulated in diseased livers and exhibited divergent IL-2-STAT5 signaling-hyperactive in CHB and HCC, suppressed in cirrhosis-indicating distinct immunosuppressive status. Lapatinib/olopatadine enhanced Treg suppressive markers in cirrhosis. Pheat provides a high-resolution atlas of hepatic T cells, revealing disease-specific immune heterogeneity and regulatory programs that inform cellular and molecular targets for potential immunotherapy.
中文摘要:单细胞转录组学极大推进了对肝脏免疫和免疫疗法的理解。然而,缺乏跨越多种肝脏疾病的综合图谱限制了免疫系统异质性和动态变化的系统比较。本研究建立了覆盖139名供体、255个血液和肝脏样本的泛肝T细胞单细胞图谱(Pheat),涵盖慢性乙型/丙型肝炎、酒精性肝炎、代谢功能障碍相关脂肪性肝炎、肝硬化、肝细胞癌及健康对照,描绘了624,215个T细胞在群体、组织和疾病层面的深刻异质性,重点聚焦CD8+耗竭T细胞和CD4+调节性T细胞。在耗竭T细胞中,与健康和对照组及其他肝病相比,慢性乙型肝炎患者肝内前体耗竭T细胞显著减少。研究鉴定并实验验证了前体耗竭T细胞中疾病特异性的检查点优势(慢性乙型肝炎中为4-1BB,肝细胞癌中为TIGIT)。泛组蛋白去乙酰化酶抑制剂帕比司他经预测和验证可重新激活慢性乙型肝炎患者的前体耗竭T细胞。同时,效应调节性T细胞在病变肝脏中积累,并表现出不同的IL-2-STAT5信号通路特征:在慢性乙型肝炎和肝细胞癌中呈超活性,而在肝硬化中受抑制,提示存在不同的免疫抑制状态。拉帕替尼/奥洛帕定增强了肝硬化中调节性T细胞的抑制标志物表达。该图谱提供了高分辨率的肝脏T细胞视图,揭示了疾病特异性的免疫异质性和调控程序,为潜在免疫疗法的细胞和分子靶点提供依据。

8功能性胃肠病 (1篇)

基础研究 (1篇)

Annual review of physiology IF 20.3 2026-11-06 PMID: 42994455
Glucagon-like peptide-1 (GLP-1) is an incretin to regulate glycemia, activates peripheral and central neural pathways to control appetite, and inhibits upper gut transit to reduce food intake. Peptide and nonpeptide GLP-1 receptor agonists (GLP-1RAs), as well as a combined GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), agonist are approved for type 2 diabetes, weight reduction, and other indications. GLP-1RA therapy can be complicated by upper gastrointestinal (GI) symptoms, including nausea and vomiting. Delayed gastric emptying secondary to GLP-1RAs may be influenced by drug pharmacokinetics, associated neuropathy, and development of tachyphylaxis with repeated dosing. A theoretical risk of pulmonary aspiration from retained gastric contents is concerning for patients undergoing anesthesia before endoscopy or surgery. Managing upper GI complications of GLP-1RA therapy includes diet modifications, antiemetic medications, and treatments that stimulate gastric emptying. Newer agents in testing include nonpeptide GLP-1RAs and GLP-1RAs acting in concert with GIP, glucagon, or other receptor-mediated pathways.
中文摘要:胰高血糖素样肽-1(GLP-1)是一种调节血糖的肠促胰岛素,通过激活外周和中枢神经通路控制食欲,并抑制上消化道蠕动以减少食物摄入。多肽及非多肽类GLP-1受体激动剂(GLP-1RAs),以及联合GLP-1和葡萄糖依赖性促胰岛素多肽(GIP)的激动剂已获批用于2型糖尿病、减重及其他适应症。GLP-1RA治疗可能伴随上消化道症状,包括恶心和呕吐。由GLP-1RAs引起的胃排空延迟可能受药物药代动力学、相关神经病变及反复给药产生的快速耐受性影响。对于接受内镜或手术前麻醉的患者而言,滞留胃内容物导致肺吸入的理论风险令人担忧。管理GLP-1RA治疗的上消化道并发症包括饮食调整、使用止吐药物以及促进胃排空的治疗。正在测试的新型制剂包括非多肽类GLP-1RAs以及与GIP、胰高血糖素或其他受体介导通路协同作用的GLP-1RAs。

9消化道肿瘤筛查 (1篇)

基础研究 (1篇)

Science advances IF 13.9 2026-11-06 PMID: 42993839
Magnetic soft robots with embodied intelligence of multimodal motions, environmental perception, and functional decoupling depend on ingenious material arrangement and programmable morphing information introduction. While some efforts have been made, achieving lifelike behaviors for soft robots in system-level strategy remains a notable challenge. Here, we present dual-programming hydrogel-based soft robots (DHSRs) that couple magnetic and anisotropic programming through the spatial arrangement of patterned magnetic skeletons into responsive and structural hydrogel bodies. These DHSRs exhibit programmable exquisite and multicurved structures in three-dimensional (3D) space, environment-adaptive deformation behaviors proved by switching from random jumping on land to regular swimming in water of a fish-like soft robot, and further locomotion-function decoupling capabilities of region-selective cargo delivery in an integrated "locomotion-perception-action" workflow. Our strategy in biomedical potential is exemplified by a ring-like pH-responsive DHSR for gastric ulcer therapy, which integrates multimodal locomotion (rolling, tumbling, and rotating), adaptive matching, and microneedle-mediated penetration. By collaborating with a capsule endoscopy system, we explore the possibility of a wireless and painless diagnostic-therapeutic platform in a pig model. This strategy endows the robot with perception and multitask execution capabilities, highlighting a promising route for the intelligent evolution of soft robots across diverse application domains.
中文摘要:具有多模态运动、环境感知和功能解耦等具身智能的磁性软机器人依赖于巧妙的材料排列和可编程形变信息的引入。尽管已有部分研究,但在系统级策略层面实现软机器人的逼真行为仍是一个显著挑战。本文提出了一种基于双编程水凝胶的软机器人(DHSRs),通过图案化磁性骨架在响应性和结构性水凝胶体中的空间排列,耦合了磁性和各向异性编程。这些DHSRs在三维空间中展现出可编程的精巧和多曲面结构,其环境自适应变形行为通过一种鱼形软机器人在陆地上的随机跳跃和在水中的规律游泳之间的切换得到证明,并进一步展示了在集成运动感知行动工作流中实现区域选择性货物递送的运动功能解耦能力。我们在生物医学潜力方面的策略以用于胃溃疡治疗的环状pH响应DHSR为例,该机器人集成了多模态运动(滚动、翻滚和旋转)、自适应匹配和微针介导的渗透。通过与胶囊内窥镜系统协作,我们在猪模型中探索了无线无痛诊断治疗平台的可能性。该策略赋予机器人感知和多任务执行能力,凸显了软机器人在不同应用领域向智能化演进的广阔前景。